SAN DIEGO, April 30, 2019 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced it will report its first quarter 2019
financial results and business progress on Tuesday, May 7, 2019, after the close of the U.S.
financial markets.
To receive Tocagen's press releases and other investor
information, please visit the Investor Relations page of the
company's website and register for email alerts.
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy
company developing first-in-class, broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. Tocagen's lead investigational product
candidate, Toca 511 & Toca FC, is under evaluation in a pivotal
Phase 3 trial (Toca 5) for recurrent high grade glioma (HGG), a
disease with significant unmet medical need. The U.S. Food and
Drug Administration awarded Tocagen an orphan drug
grant for the Toca 5 trial and has granted Toca 511 & Toca FC
Breakthrough Therapy Designation for the treatment of recurrent
HGG. The European Medicines Agency has granted Toca 511
PRIME (PRIority MEdicines) designation for the treatment of
glioma.
Media Contact:
Pam Lord
Canale Communications
(619) 849-6003
pam@canalecomm.com
Investor Contact:
Pete Rahmer
Endurance Advisors
(415) 515-9763
prahmer@enduranceadvisors.com
SOURCE Tocagen Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/tocagen-to-report-first-quarter-2019-financial-and-business-results-on-tuesday-may-7-300840682.html
SOURCE Tocagen Inc.